US FDA approves herpes zoster vaccine for adults aged 50 years and older
162 Views
eMediNexus 24 October 2017
The US FDA has approved recombinant zoster vaccine (adjuvanted) to prevent herpes zoster in adults aged 50 years and older. The vaccine, Shingrix, includes glycoprotein E, an antigen and AS01B, an adjuvant system. It is to be administered in two doses, at a gap of 2-6 months.
To comment on this article, create a free account.
Sign Up to instantly get access to 10000+ Articles & 1000+ Cases
eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.